Effectiveness and Efficiency of Government Health Insurance in India: Impacts of Strengthening Hospital Monitoring and Fraud Control

Last registered on June 25, 2024

Pre-Trial

Trial Information

General Information

Title
Effectiveness and Efficiency of Government Health Insurance in India: Impacts of Strengthening Hospital Monitoring and Fraud Control
RCT ID
AEARCTR-0013744
Initial registration date
June 18, 2024

Initial registration date is when the trial was registered.

It corresponds to when the registration was submitted to the Registry to be reviewed for publication.

First published
June 25, 2024, 10:40 AM EDT

First published corresponds to when the trial was first made public on the Registry after being reviewed.

Locations

There is information in this trial unavailable to the public. Use the button below to request access.

Request Information

Primary Investigator

Affiliation
Princeton University

Other Primary Investigator(s)

PI Affiliation
UCL
PI Affiliation
Princeton University

Additional Trial Information

Status
On going
Start date
2023-07-01
End date
2025-12-31
Secondary IDs
Prior work
This trial does not extend or rely on any prior RCTs.
Abstract
This study seeks to identify government interventions that can improve the efficiency of public health insurance schemes without reducing their effectiveness. We conduct a statewide RCT that randomizes an intervention to increase the threat of crackdown on hospital fraud across private hospitals in one state of India. We leverage administrative data from the insurance program and augment it with patient surveys to measure impacts on hospital fraud, as well as patient out-of-pocket charges, care access, and care quality. The study will provide some of the first evidence on hospital fraud and monitoring within insurance in LMICs. It will also provide insights on the design and effectiveness of monitoring (auditing) systems given limited state resources that generalize to social insurance and assistance programs more broadly.
External Link(s)

Registration Citation

Citation
Dupas, Pascaline, Radhika Jain and Yinshan Shang. 2024. "Effectiveness and Efficiency of Government Health Insurance in India: Impacts of Strengthening Hospital Monitoring and Fraud Control." AEA RCT Registry. June 25. https://doi.org/10.1257/rct.13744-1.0
Sponsors & Partners

Sponsors

There is information in this trial unavailable to the public. Use the button below to request access.

Request Information
Experimental Details

Interventions

Intervention(s)
Treatment hospitals receive a government letter, signed by the CEO of the health insurance scheme, warning them that the insurance authorities are increasing fraud controls and that their audit probability has increased. The letters are intended to abruptly increase hospitals’ perceived threat of fraud detection, which has been shown to deter fraud in other contexts.
A second intervention is potentially scheduled for later. In this second intervention, the insurance trust would conduct hospital audits at randomly selected hospitals in both treatment and control groups. We are not yet sure this will be possible as it depends on the insurance trust's capacity. We will file an update to the registry entry to update this part of the protocol when plans have been finalized.
Intervention Start Date
2024-03-28
Intervention End Date
2024-09-30

Primary Outcomes

Primary Outcomes (end points)
Our main outcomes will be: (a) composition of claims (including measures of upcoding, duplication, and unbundling of claims, estimated from analyses of claims and survey data); (b) claims volume, as observed in administrative data; and (c) average out-of-pocket charges paid by patients, as measured through exit phone surveys.
Primary Outcomes (explanation)
The key hypotheses are as follows:
1. If hospitals respond by reducing fraud, we should see a decrease in our measures of upcoding, duplication and unbundling.
2. If hospitals respond by turning away patients perceived as low-value from the standpoint of hospital’s profit (e.g., patients whose care costs would potentially surpass the pay rate absent upcoding or OOPP charges), we should see a decrease in (b).
3. If they compensate by increasing OOPP, we should see an increase in (c).
For all outcomes of interest, we will be estimating averages at the hospital-specialty level. The patient surveys have specialty-specific questions for a subset of specialties (in depth modules for pediatrics and obgyn, and lighter modules for cardiology, genitourinary and orthopedics) so analyses will vary in depth across these specialties. We will cluster the standard errors at the hospital level, since the randomization will be at the hospital level.
We will use a combination of administrative data, patient surveys, and government audits data.

Secondary Outcomes

Secondary Outcomes (end points)
Patient-reported care quality (including skimping on care that is less profitable in the absence of fraud),
Patient selection (turning away sicker/costlier or poorer patients).
Secondary Outcomes (explanation)

Experimental Design

Experimental Design
Using historical data on claims, we identified private hospitals with relatively high claim volumes and values. Within these, hospitals were randomly selected for the "treatment" (letter intervention). We stratified the letter intervention randomization by what specialties the hospital offers (in particular whether or not the hospital offers the specialties targeted in the patient surveys), baseline average claims value, hospital share of district-level claims, and whether it is located outside AP state.

Public hospitals are not included in the RCT, but we will be able to use their claiming patterns over time as a useful benchmark since their incentives to manipulate claims are minimal.
Experimental Design Details
Not available
Randomization Method
randomization done in office by computer
Randomization Unit
hospital
Was the treatment clustered?
No

Experiment Characteristics

Sample size: planned number of clusters
340 hospitals
Sample size: planned number of observations
339 hospitals
Sample size (or number of clusters) by treatment arms
169 Treatment, 170 Control
Minimum detectable effect size for main outcomes (accounting for sample design and clustering)
IRB

Institutional Review Boards (IRBs)

IRB Name
IFMR-IRB
IRB Approval Date
2023-09-04
IRB Approval Number
N/A
IRB Name
Princeton RIA
IRB Approval Date
2023-10-16
IRB Approval Number
15949